Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
64
datasets available to search
ShareScore release 0.9.0
Dataset results
64 results for “Preclinical studies”
Combined proton radiography and irradiation for high-precision preclinical studies in small animals
<p>Data used for the publication "Combined proton radiography and irradiation for high-precision preclinical studies in small animals".</p> <p>The repository contains all data that was used to generate the quantitative results and figures in the submitted manuscript.</p> <p>Further documentation for the provided code can be found here: https://github.com/jo-mueller/radiographic_workflow_evaluation</p>
Dataset related to article "Systematic review and meta-analysis of preclinical studies testing mesenchymal stromal cells for traumatic brain injury"
<p>Mesenchymal stromal cells (MSCs) are widely used in preclinical models of traumatic brain injury (TBI). Results are promising in terms of neurological improvement but are hampered by wide variability in treatment responses. We made a systematic review and meta-analysis: 1) to assess the quality of evidence for MSC treatment in TBI rodent models; 2) to determine the effect size of MSCs on sensorimotor function, cognitive function and anatomical damage; 3) to identify MSC-related and protocol-related variables associated with greater efficacy; 4) to understand whether MSC manipulations boost therapeutic efficacy.</p> <p>The meta-analysis included 80 studies. After TBI, MSCs improved sensorimotor and cognitive deficits, and reduced anatomical damage. Stratified meta-analysis on sensorimotor outcome showed similar efficacy for different MSC sources and for syngeneic or xenogenic transplants. Efficacy was greater when MSCs were delivered in the first week post-injury, and when implanted directly into the lesion cavity. The greatest effect size was for cells embedded in matrices or for MSC-derivatives.</p> <p>MSC therapy is effective in preclinical TBI models, improving sensorimotor, cognitive and anatomical outcomes, with large effect sizes. These findings support clinical studies in TBI.</p> <p>The present dataset reports extrapolated data used for the meta-analysis</p>
Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)
ClinicalTrials.gov study NCT01970176. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Includi
ClinicalTrials.gov study NCT01998841. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3)
ClinicalTrials.gov study NCT02058095. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effects of the Hypnotic Alkylphenol Derivative Propofol on Breast Cancer Progression. A Focus on Preclinical and Clinical Studies.
<p>Propofol is a hypnotic alkylphenol derivative with many biological activities. It is predominantly used in anesthesia and is the most used parenteral anesthetic agent in the United States. Accumulating preclinical studies have shown that this compound may inhibit cancer recurrence and metastasis. Nevertheless, other investigations provided evidence that this compound may promote breast cancer cell progression by modulating different molecular pathways. Clinical data on this topic are scarce and derive from retrospective analyses. For this reason, we reviewed and evaluated the available data to reveal insight into this controversial issue. More preclinical and clinical investigations are necessary to determine the potential role of propofol in the proliferation of breast cancer cells.</p>
A Natural History Study of Preclinical Genetic Creutzfeldt-Jakob Disease (CJD)
ClinicalTrials.gov study NCT05746715. IPD Sharing: NO. Countries: 1. Publications: 2.
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study
ClinicalTrials.gov study NCT05245344. IPD Sharing: NO. Countries: 1. Publications: 32.
Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
ClinicalTrials.gov study NCT00457587. IPD Sharing: Not stated. Countries: 1. Publications: 1.
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Prec
ClinicalTrials.gov study NCT04468659. IPD Sharing: YES. Countries: 7. Publications: 4.
Preclinical Studies of Omalizumab in Chronic Rhinosinusitis With Nasal Polyposis
ClinicalTrials.gov study NCT04583501. IPD Sharing: NO. Countries: 1. Publications: 5.
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
ClinicalTrials.gov study NCT05026866. IPD Sharing: YES. Countries: 3. Publications: 1.
Data from: The relationship between risk of bias criteria, research outcomes, and study sponsorship in a cohort of preclinical thiazolidinedione animal studies: a meta-analysis
Introduction: There is little evidence regarding the influence of conflicts of interest on preclinical research. This study examines whether industry sponsorship is associated with increased risks of bias and/or effect sizes of outcomes in published preclinical thiazolidinedione (TZD) studies. Methods: We identified preclinical TZD studies published between January 1, 1965, and November 14, 2012. Coders independently extracted information on study design criteria aimed at reducing bias, results for all relevant outcomes, sponsorship source and investigator financial ties from the 112 studies meeting the inclusion criteria. The average standardized mean difference (SMD) across studies was calculated for plasma glucose (efficacy outcome) and weight gain (harm outcome). In subgroup analyses, TZD outcomes were assessed by sponsorship source and risk of bias criteria. Results: Seven studies were funded by industry alone, 17 studies funded by both industry and non-industry, 49 studies funded by non-industry alone and 39 studies had no disclosures. None of the studies used sample size calculations, intention-to-treat analyses, blinding of investigators or concealment of allocation. Most studies reported favourable results (88 of 112) and conclusions (95 of 112) supporting TZD use. Efficacy estimates were significantly larger in six studies sponsored by industry alone (−3.41; 95% CI −5.21, −1.53; I2 = 93%) versus 42 studies sponsored by non-industry sources (−0.97; 95% CI −1.37, −0.56; I2 = 81%; p-value = 0.01). Harms estimates were significantly larger in four studies sponsored by industry alone (5.00; 95% CI 1.22, 8.77; I2 = 93%) versus 38 studies sponsored by non-industry sources (0.30; 95% CI −0.08, 0.68; I2 = 79%; p-value = 0.02). TZD efficacy and harms did not differ by disclosure of financial COIs or risks of bias. Conclusions: Industry-sponsored TZD animal studies have exaggerated efficacy and harms outcomes compared with studies funded by non-industry sources. There was poor reporting of COIs.
Figure 6 from: Shannag S, Nuseir K, Tahaineh L, Hananeh W (2024) Curcumin is comparable to metformin for the treatment of PCOS in rats: a preclinical study. Pharmacia 71: 1-10. https://doi.org/10.3897/pharmacia.71.e119708
Figure 6 Ovarian section from G6 group showing disrupted follicular development, lack of corpora lutea and presence of follicular cysts.
Figure 3 from: Shannag S, Nuseir K, Tahaineh L, Hananeh W (2024) Curcumin is comparable to metformin for the treatment of PCOS in rats: a preclinical study. Pharmacia 71: 1-10. https://doi.org/10.3897/pharmacia.71.e119708
Figure 3 Hormonal and metabolic serum levels over time. Changes in serum levels of testosterone, estradiol, progesterone, and glucose before and after treatment with metformin, curcumin, metformin + curcumin, and olive oil compared to control rats' side by side. Data expressed as mean ± SEM (n = 16–17).
Figure 5 from: Shannag S, Nuseir K, Tahaineh L, Hananeh W (2024) Curcumin is comparable to metformin for the treatment of PCOS in rats: a preclinical study. Pharmacia 71: 1-10. https://doi.org/10.3897/pharmacia.71.e119708
Figure 5 Ovarian section from G3 group showing multiple variably sized follicular cysts with disrupted normal follicular development.
Figure 2 from: Shannag S, Nuseir K, Tahaineh L, Hananeh W (2024) Curcumin is comparable to metformin for the treatment of PCOS in rats: a preclinical study. Pharmacia 71: 1-10. https://doi.org/10.3897/pharmacia.71.e119708
Figure 2 Hormonal and metabolic serum levels. Changes in serum levels of testosterone, estradiol, progesterone, and glucose before and after treatment with metformin, curcumin, metformin + curcumin, and olive oil compared to control rats. Data expressed as mean ± SEM (n = 16–17). *Significantly different form control. A. Testosterone levels in ng/ml following letrozole injections and before treatment at age 9 weeks; B. Estradiol levels in pg/ml following letrozole injections and before treatment at age 9 weeks; C. Progesterone levels in ng/ml following letrozole injections and before treatment at age 9 weeks; D. Glucose serum levels mg/dl following letrozole injections and before treatment at age 9 weeks; E. Testosterone levels in ng/ml following treatment at age 12 weeks; F. Estradiol levels in pg/ml following treatment at age 12 weeks; G. Progesterone levels in ng/ml following treatment at age 12 weeks; H. Glucose serum levels mg/dl following treatment at age 12 weeks.
Figure 4 from: Shannag S, Nuseir K, Tahaineh L, Hananeh W (2024) Curcumin is comparable to metformin for the treatment of PCOS in rats: a preclinical study. Pharmacia 71: 1-10. https://doi.org/10.3897/pharmacia.71.e119708
Figure 4 Ovarian section from control group showing different stages of follicular development and normal ovarian morphology.
Figure 1 from: Shannag S, Nuseir K, Tahaineh L, Hananeh W (2024) Curcumin is comparable to metformin for the treatment of PCOS in rats: a preclinical study. Pharmacia 71: 1-10. https://doi.org/10.3897/pharmacia.71.e119708
Figure 1 Changes in body weight before (DI, week 6) PCOS induction, after PCOS induction (T, week 9), and following treatments (sac, week 12) with metformin, curcumin, combination of met +cur and olive oil. Data expressed as mean ± SEM (n = 16–17). ** significant difference from control group.
CSF synaptic biomarkers in the preclinical stage of Alzheimer's disease and their association with MRI and PET markers of neurodegeneration: a cross-sectional study
<p>Objective: To determine whether CSF synaptic biomarkers are altered in the early preclinical stage of the Alzheimer's <i>continuum</i> and associated with Alzheimer's disease (AD) risk factors, primary pathology, and neurodegeneration markers.</p> <p>Methods: Cross-sectional study in the ALFA+ cohort, comprising middle-aged cognitively unimpaired participants. CSF neurogranin and GAP-43 were measured using immunoassays and SNAP-25 and synaptotagmin-1 using immunoprecipitation mass spectrometry. AD CSF biomarkers Aβ42/40, p-tau and t-tau, and the neurodegeneration biomarker NfL were also measured. Participants underwent structural MRI, and <span>fluorodeoxyglucose and</span> Aβ<span> PET imaging. General linear modeling was used to test the associations between CSF synaptic biomarkers and risk factors, </span>Aβ<span> pathology, tau pathology, and neurodegeneration markers.</span></p> <p>Results: All CSF synaptic biomarkers increased with age. CSF neurogranin was higher in females, while CSF SNAP-25 was higher in <i>APOE-</i>ε4 carriers. All CSF synaptic biomarkers increased with higher Aβ load (as measured by CSF Aβ42/40 and Aβ PET Centiloid values) and, importantly, the synaptic biomarkers were increased even in individuals in the earliest stages of Aβ deposition. Higher CSF synaptic biomarkers were also associated with higher CSF p-tau and NfL. Higher CSF neurogranin and GAP-43 were significantly associated with higher brain metabolism, but lower cortical thickness in AD-related brain regions.</p> <p>Conclusion: CSF synaptic biomarkers increase in early preclinical stages of the Alzheimer's <i>continuum </i>even when a low burden of Aβ pathology is present, and they differ in their association with age, sex, <i>APOE-</i>ε4<i>,</i> and markers of neurodegeneration.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.